Syneos Health announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors. Following the appointment of Ms. Bodem and Mr. Zulueta, the Syneos Health Board is comprised of 11 directors, 10 of whom are independent. Ms. Bodem will serve as a Class I director and will serve on the Company's Audit Committee and Mr. Zulueta will serve as a Class III director.

Ms. Bodem currently serves on the board of directors of Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a clinical-stage precision oncology company, where she serves as Chair of the Audit Committee and as a member of the Compensation Committee. Mr. Zulueta currently serves on the board of directors of CTS Corporation (NYSE: CTS), a global manufacturer of sensors, connectivity components, and actuators, where he serves on the Audit Committee; Compensation Committee; and Nominating, Governance, and Sustainability Committee.